Table 2.
18F-FDG accumulation in the mainly involved organs and tissues in patients with AOSD compared with healthy controls
| N (%) | SUVmax in patients with AOSD | Bilateral (n) | SUVmax in healthy controls | p | |
|---|---|---|---|---|---|
| Bone marrow | – | 5.10 (4.25–6.10) | – | 3.76 (3.00–4.15) | < 0.001 |
| Spleen | – | 3.70 (3.05–4.35) | – | 2.28 (2.06–2.56) | < 0.001 |
| Liver | – | 3.20 (2.80–3.60) | – | 3.26 (2.88–3.58) | 0.672 |
| Lymph nodes# | 38 (66.67) | 5.55 (4.05–8.68) | – | – | – |
| Cervical LN | 30 (52.63) | 5.15 (3.92–7.85) | 26/30 | – | – |
| Axillary LN | 27 (47.37) | 4.70 (2.70–6.00) | 25/27 | – | – |
| Mediastinum LN | 19 (33.33) | 5.30 (3.70–8.90) | – | – | – |
| Pelvic LN | 16 (28.07) | 6.45 (4.68–8.52) | – | – | – |
| Retroperitoneal LN | 14 (24.56) | 5.60 (3.15–7.72) | – | – | – |
| Inguinal LN | 13 (22.81) | 4.20 (2.65–5.20) | 10/13 | – | – |
| Abdominal LN | 8 (14.04) | 6.60 (5.25–7.70) | – | – | – |
Data are presented in the form of median (Q1–Q3) as continuous variable
SUV standardized uptake value
#This was calculated from the patients with hypermetabolic lymph nodes (n = 38). SUVmax was the maximum SUV of the regional lymph node